FOX Translator
No data currently available.
No data currently available.
You know that buying a stock makes you part owner of a company, theoretically with millions of other people. But, while ownership has its privileges (at minimum you get a neat stock certificate and an invitation to the annual meeting), being an owner doesn't necessarily pay. Sure, you make money if the stock goes up, but only if you sell, and you can, in theory, lose all the value of your investment if the stock tanks.
Enter the dividend. Here, you get money simply from holding the stock. Companies pay a yield, which is expressed in a percentage based on the stock's price. For example, if a stock trades at $10, and pays a 10% annual yield, your dividend payment would be a $1. (Usually, companies break out the payments quarterly, so, using our example, you¿d get, well, a quarter each quarter.)
Companies that pay dividends fall into a few categories. First, you've got your big, stable companies that generate enough cash that it makes sense to throw some back to shareholders. Next, there are businesses, like real estate investment trusts, that are in the business of sitting back and receiving cash, then distributing it to holders. And, then there are companies that need to dangle a high dividend yield like a carrot to ease investor fears. Cigarette-maker Altria has been doing this for years.
Simply because a company pays a dividend doesn't make it a good investment. After all, you may want to take a chance on a growth stock that can move higher in price than dividend payers are known to do. But, you can¿t beat the safety of knowing that, even if a stock doesn't move in a year, you¿re at least making something off your investment.
Home / Markets / Industries / Media
Monday, June 23, 2008
Elsevier to Contribute 9 Million Articles to CrossCheck
Comtex
AMSTERDAM, Jun 23, 2008 (PR Newswire Europe via COMTEX) ----Ready to Implement CrossRef's Plagiarism Detection Software After Successful Pilot
Elsevier, the leading publisher of science, technology and medical information announced today that it will implement CrossCheck, the plagiarism detection service offered by CrossRef in collaboration with iParadigms. With plagiarism a growing problem for journal editors, Elsevier has invested in CrossCheck to develop, pilot and implement, a single database of published articles enabling publishers to easily verify the originality of submitted and published work.
After a successful six months pilot with eight leading publishers, Elsevier is now in the process of integrating CrossCheck into its editorial workflows as part of its efforts to support the peer review process and assist the scientific community in all aspects of publishing ethics. Elsevier will contribute nearly nine million journal articles to the CrossCheck database, which is launching with a commitment of over 20 million journal articles from publishers including the Association for Computing Machinery, American Society of Neuroradiology, BMJ Publishing Group, Elsevier, Institute of Electrical & Electronics Engineers, International Union of Crystallography , The Journal of the American Medical Association, Nature Publishing Group, Oxford University Press, Sage, Informa UK (Taylor & Francis), and Wiley Blackwell.
"By creating a pooled database of articles from multiple publishers and tested tools, we can provide assistance to the scholarly community on an unprecedented scale," commented Martin Tanke, Elsevier's Managing Director of S&T Journal Publishing, "CrossRef has taken the principles of publisher collaboration far beyond reference linking. CrossCheck, combined with our recently launched Publishing Ethics Resource Kit and full journal membership in COPE (Committee on Publishing Ethics) further reinforce our commitment."
"CrossRef took the initiative to create this co-operative publisher service, which we greatly appreciate. This is a tremendous development and we are delighted that this collaboration has been so fruitful," said Karen Hunter, Senior Vice President Global Academic & Customer Relations and Elsevier's CrossRef Board member, "The iParadigms software is impressive and we are look forward to working with them."
John Barrie, Ph.D, president and CEO of iParadigms, LLC added, "Our customers, especially academic ones, have been asking for more medical and science content for checking the originality of work destined for publication. Elsevier's adoption of CrossCheck powered by iThenticate lets us leverage their vast, industry-leading content to significantly enhance the effectiveness of our originality checking services. Likewise, Elsevier will leverage the CrossCheck and iParadigms database which makes for a powerful alliance and one that is extremely beneficial to our network of institutional subscribers."
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult ( http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Contact: Ylann Schemm, Phone: +31-20-485-2025, E-mail: y.schemm@elsevier.com
Contact: Ylann Schemm, Phone: +31-20-485-2025, E-mail: y.schemm@elsevier.com
Copyright (C) 2008 PR Newswire Europe ********************************************************************** As of Thursday, 06-19-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a DOWNTREND on 05-27-2008 for ENL @ $36.31. As of Thursday, 06-19-2008 23:59, the latest Comtex SmarTrend Alert, an automated pattern recognition system, indicated a DOWNTREND on 05-23-2008 for RUK @ $49.06. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights reserved.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
